IL263568A - Process for the production of a dna vaccine for cancer immunotherapy - Google Patents

Process for the production of a dna vaccine for cancer immunotherapy

Info

Publication number
IL263568A
IL263568A IL263568A IL26356818A IL263568A IL 263568 A IL263568 A IL 263568A IL 263568 A IL263568 A IL 263568A IL 26356818 A IL26356818 A IL 26356818A IL 263568 A IL263568 A IL 263568A
Authority
IL
Israel
Prior art keywords
producing
dna vaccine
cancer immunotherapy
immunotherapy
cancer
Prior art date
Application number
IL263568A
Other languages
English (en)
Hebrew (he)
Inventor
Lubenau Heinz
Original Assignee
Vaximm Ag
Lubenau Heinz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaximm Ag, Lubenau Heinz filed Critical Vaximm Ag
Publication of IL263568A publication Critical patent/IL263568A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103Receptors for growth factors
    • A61K39/001109Vascular endothelial growth factor receptors [VEGFR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001166Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168Mesothelin [MSLN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00118Cancer antigens from embryonic or fetal origin
    • A61K39/001182Carcinoembryonic antigen [CEA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL263568A 2016-07-13 2018-12-06 Process for the production of a dna vaccine for cancer immunotherapy IL263568A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16001550 2016-07-13
PCT/EP2017/067590 WO2018011289A1 (en) 2016-07-13 2017-07-12 Process for the production of a dna vaccine for cancer immunotherapy

Publications (1)

Publication Number Publication Date
IL263568A true IL263568A (en) 2019-01-31

Family

ID=56418345

Family Applications (1)

Application Number Title Priority Date Filing Date
IL263568A IL263568A (en) 2016-07-13 2018-12-06 Process for the production of a dna vaccine for cancer immunotherapy

Country Status (13)

Country Link
US (2) US10821163B2 (https=)
EP (1) EP3484503A1 (https=)
JP (2) JP7098599B2 (https=)
KR (3) KR20190027834A (https=)
CN (1) CN109475614A (https=)
AU (1) AU2017295004B2 (https=)
BR (1) BR112019000657A2 (https=)
CA (1) CA3028549A1 (https=)
IL (1) IL263568A (https=)
MX (1) MX2019000415A (https=)
RU (1) RU2019100079A (https=)
SG (1) SG11201811258UA (https=)
WO (1) WO2018011289A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018149982A1 (en) * 2017-02-17 2018-08-23 Vaximm Ag Novel vegfr-2 targeting immunotherapy approach
EP3652318A1 (en) 2017-07-11 2020-05-20 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
JP7340591B2 (ja) 2018-07-11 2023-09-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
JP7598315B2 (ja) * 2018-09-05 2024-12-11 エンエーセー オンコイミュニティ アクスイェ セルスカプ 併用療法用dnaワクチンを標的とするネオアンチゲン
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US20230121528A1 (en) 2020-01-13 2023-04-20 Vaximm Ag Salmonella-based dna vaccines in combination with an antibiotic
WO2024005122A1 (ja) * 2022-06-30 2024-01-04 株式会社島津製作所 微生物の分析の準備方法、および、微生物の分析方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3892295T3 (pl) * 2011-05-24 2023-07-24 BioNTech SE Zindywidualizowane szczepionki przeciwnowotworowe
CA2853656C (en) * 2011-12-22 2020-12-29 Vaximm Ag Method of producing high yield attenuated salmonella strains
JP6325534B2 (ja) 2012-07-05 2018-05-16 バクシム アクチェンゲゼルシャフト 膵臓癌患者用dnaワクチン
MX364922B (es) * 2013-04-25 2019-05-14 Vaximm Ag Vacuna de adn que dirige wt-1 novedosa para inmunoterapia contra cáncer.
SI3082850T1 (sl) * 2013-12-18 2020-01-31 Vaximm Gmbh DNA cepivo, ki cilja MSLN za imunoterapijo raka
KR20230076867A (ko) * 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법

Also Published As

Publication number Publication date
AU2017295004B2 (en) 2020-08-13
EP3484503A1 (en) 2019-05-22
AU2017295004A1 (en) 2019-01-03
RU2019100079A (ru) 2020-08-13
US11590215B2 (en) 2023-02-28
KR20190027834A (ko) 2019-03-15
WO2018011289A1 (en) 2018-01-18
JP2022097591A (ja) 2022-06-30
JP2019521154A (ja) 2019-07-25
BR112019000657A2 (pt) 2019-04-24
JP7098599B2 (ja) 2022-07-11
US10821163B2 (en) 2020-11-03
US20190183996A1 (en) 2019-06-20
CN109475614A (zh) 2019-03-15
KR20230079514A (ko) 2023-06-07
CA3028549A1 (en) 2018-01-18
SG11201811258UA (en) 2019-01-30
US20220072112A1 (en) 2022-03-10
MX2019000415A (es) 2019-03-28
KR20260047288A (ko) 2026-04-07

Similar Documents

Publication Publication Date Title
IL264023A (en) Nant cancer vaccine
IL285722A (en) Methods for treating alzheimer's disease
EP3630130A4 (en) PROCESS FOR GENERATING PERSONALIZED CANCER VACCINES
IL263568A (en) Process for the production of a dna vaccine for cancer immunotherapy
EP3576751A4 (en) RNA ANTI-CANCER VACCINES
SG11201706593SA (en) Methods for producing virus for vaccine production
EP3302794A4 (en) epoxidation
SG10201913631TA (en) Rna for cancer therapy
EP3378869A4 (en) PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES
GB2572275B (en) Method for preparing Foot-and-Mouth disease vaccine
EP3392266A4 (en) LINACLOTIDSYNTHESEVERFAHREN
MA52906A (fr) Procédé de préparation d'amg 416
EP3439793A4 (en) AEROSOL GENERATING DEVICE
EP3398957A4 (en) PROCESS FOR SYNTHESIS OF ETELCALCETIDE
IL268677A (en) Novel pd-l1 targeting dna vaccine for cancer immunotherapy
EP3296282A4 (en) METHOD FOR PRODUCING HYDROHALOGEN FLUOROLEFINES
EP3498837A4 (en) GENOMEDITATION PROCEDURE
IL277752A (en) Cancer vaccines
EP3497088A4 (en) epoxidation
MA46454A (fr) Procédé multi-protéase
EP3441761A4 (en) FLUORESZENZIMMUNFÄRBEVERFAHREN
GB201619827D0 (en) Process for the production of methyl methacrylate
EP3558903A4 (en) METHOD
IL277956B1 (en) Process for the preparation of iloprost
EP3484860A4 (en) epoxidation